Expert Financial Analysis and Reporting

Introduction I have included an abstract on DCVax Direct and another on DCVax-L that will be presented in poster presentations at the American Association of Cancer Research (AACR) meeting during April 18 to April 22. I have included the entire abstract for your review DCVax Direct Poster This poster dealt with the phase 1 trial […]

The $40 million will fund the Company through the end of 2015. CEO Linda Powers indicates that this is the cornerstone of the Company’s financing plans. I am speculating that there will be as much as $60 million more capital raised this year that will take the Company well past topline DCVax-L data in 2016. […]

Introduction Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the 51 patient information arm of the DCVax-L phase 3 trial. This marks the 22nd consecutive negative blog by Feuerstein on Northwest. I am growing tired of rebutting his articles, but as long as he […]

Executive Summary Northwest Biotherapeutics has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed glioblastoma multiforme. They became ineligible when their cancer progressed before they could enter the trial. However, they were treated nearly identically to the […]

Introduction Northwest Biotherapeutics just issued their 10-K for 2014 and I would urge everyone to read it. The purpose of this note is to point out what I consider to be interesting pieces of information gleaned from the 10-K. Once a year, each Company publishes a 10-K and I think of the document as a […]

There has been a lot of speculation about how much it costs to manufacture one course of individualized therapy of DCVax-L. In its manufacturing process, autologous living cells are removed from the patient’s body, manipulated ex vivo and then injected back into the body. This may take seven to eight days, has a number of […]

The BIO CEO Conference is being held in New York at the Waldorf Astoria on February 9 and 10 with a broad agenda of companies. You can go the websites of each company to hear their presentations. This note gives some highlights from the first day. Northwest Biotherapeutics; A paper discussing results from the phase […]

Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the agenda as a speaker in which she explained Northwest’s business strategy and as a participant on a panel […]

Ms. Powers will present at 10:30 AM. She will then participate in a discussion panel with representatives from Amgen, Roche Diagnostics, Adaptimmune and Biovest International. Prior to her presentation representatives from Bristol-Myers Squibb, Merck and M.D. Anderson will speak. I don’t know if there will be anything new that will be presented but inclusion of […]

Overview Linda Powers spoke at the Biotech Showcase Conference in San Francisco on January 12, 2015. My Buy recommendation on Northwest Biotherapeutics is well documented and well known. The purpose of this note is not to document the reasons for my positive recommendation. It is intended as a brief summary of the notes that I took. […]